Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

Cost-effectiveness study of oral hypoglycemic agents in the treatment of outpatients with type 2 diabetes attending a public primary care clinic in Mexico City.

Díaz de León-Castañeda C, Altagracia-Martínez M, Kravzov-Jinich J, Cárdenas-Elizalde Mdel R, Moreno-Bonett C, Martínez-Núñez JM.

Clinicoecon Outcomes Res. 2012;4:57-65. doi: 10.2147/CEOR.S27826.

2.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
3.

Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a german statutory healthcare perspective.

Neeser K, Lübben G, Siebert U, Schramm W.

Pharmacoeconomics. 2004;22(5):321-41. Review.

PMID:
15061682
4.

Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada.

Tunis SL, Sauriol L, Minshall ME.

Appl Health Econ Health Policy. 2010;8(4):267-80. doi: 10.2165/11535380-000000000-00000.

PMID:
20578781
5.

Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.

Schwarz B, Gouveia M, Chen J, Nocea G, Jameson K, Cook J, Krishnarajah G, Alemao E, Yin D, Sintonen H.

Diabetes Obes Metab. 2008 Jun;10 Suppl 1:43-55. doi: 10.1111/j.1463-1326.2008.00886.x.

PMID:
18435673
6.

Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.

Wang JS, Lin SD, Lee WJ, Su SL, Lee IT, Tu ST, Tseng YH, Lin SY, Sheu WH.

Clin Ther. 2011 Dec;33(12):1932-42. doi: 10.1016/j.clinthera.2011.10.014.

PMID:
22078152
7.

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.

Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R.

Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. Review.

8.

Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation.

Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor RJ, Fry-Smith A, Day E, Lintzeris N, Roberts T, Burls A, Taylor RS.

Health Technol Assess. 2007 Mar;11(9):1-171, iii-iv. Review.

9.

Liraglutide for the treatment of type 2 diabetes.

Shyangdan D, Cummins E, Royle P, Waugh N.

Health Technol Assess. 2011 May;15 Suppl 1:77-86. doi: 10.3310/hta15suppl1/09. Review.

10.
11.

Cost effectiveness of ACE inhibitor treatment for patients with type 1 diabetes mellitus.

Dong FB, Sorensen SW, Manninen DL, Thompson TJ, Narayan V, Orians CE, Gregg EW, Eastman RC, Dasbach EJ, Herman WH, Newman JM, Narva AS, Ballard DJ, Engelgau MM.

Pharmacoeconomics. 2004;22(15):1015-27.

PMID:
15449965
12.

Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.

Valentine WJ, Palmer AJ, Lammert M, Langer J, Brändle M.

Clin Ther. 2011 Nov;33(11):1698-712. doi: 10.1016/j.clinthera.2011.09.022.

PMID:
22018679
13.

Cost and clinical implications of diabetes prevention in an Australian setting: a long-term modeling analysis.

Palmer AJ, Tucker DM.

Prim Care Diabetes. 2012 Jul;6(2):109-21. doi: 10.1016/j.pcd.2011.10.006.

PMID:
22153888
14.

A short-term cost-of-treatment model for type 2 diabetes: comparison of glipizide gastrointestinal therapeutic system, metformin, and acarbose.

Ramsdell JW, Grossman JA, Stephens JM, Botteman MF, Arocho R.

Am J Manag Care. 1999 Aug;5(8):1007-24.

15.

Economic model of first-line drug strategies to achieve recommended glycaemic control in newly diagnosed type 2 diabetes mellitus.

Ramsdell JW, Braunstein SN, Stephens JM, Bell CF, Botteman MF, Devine ST.

Pharmacoeconomics. 2003;21(11):819-37.

PMID:
12859222
16.

A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US.

St Charles M, Minshall ME, Pandya BJ, Baran RW, Tunis SL.

Curr Med Res Opin. 2009 Jun;25(6):1343-53. doi: 10.1185/03007990902870084. Erratum in: Curr Med Res Opin. 2009 Jun;25(6):1353.

PMID:
19419339
17.

Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain.

Shearer AT, Bagust A, Ampudia-Blasco FJ, Martínez-Lage Alvarez B, Pérez Escolano I, París G.

Pharmacoeconomics. 2006;24 Suppl 1:49-59. Review.

PMID:
16800162
18.

Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China.

Gao L, Zhao FL, Li SC.

Int J Technol Assess Health Care. 2012 Oct;28(4):436-44. doi: 10.1017/S0266462312000608.

PMID:
23006540
19.

The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.

Fox M, Mealing S, Anderson R, Dean J, Stein K, Price A, Taylor RS.

Health Technol Assess. 2007 Nov;11(47):iii-iv, ix-248. Review.

Items per page

Supplemental Content

Support Center